US4474690A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the recovery of peptide-containing compound and means therefor
Assignee: Gambro Lundia AB
•
Filing: 1983-06-01
•
Granted: 1984-10-02
•
Expires: 2003-06-01
Abstract
Abstract A method is disclosed for the recovery of a peptide-containing compound from a solution by the use of a ligand attached to a carrier which ligand is capable by biospecific affinity of fixing onto the peptide-containing compound. The carrier which, for example, may be a soluble macromolecule, e.g., cellulose or dextran, with ligand attached thereto, is utilized in dissolved form. The choice of ligand is determined by the type of peptide-containing compound for which it is to be used. Example of ligands which may be used are immunoglobulins, Fc-receptors, certain surface receptors from bacteria, e.g., protein A from S. aureus, co-factors and certain sugar-containing proteins. The ligand may be attached to the carrier by bonds of a covalent character, which may be achieved by periodate activation and subsequent coupling or by diimidazole coupling.
Inventors
- 👤 Ulf Nylen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 06:51
CPC Classifications
C; C12; C12N; C12N9/00; B; B01; B01D; B01D15/00; B01D15/08; B01D15/10; B01D15/12; B01D15/125; B01D15/26; B01D15/38; B01D15/3804; B01D15/3809; B01D61/00; B01D61/14; B01D61/147; B01D61/18; B01D63/00; B01D63/02; C07; C07K; C07K1/00; C07K1/14; C07K1/16; C07K1/22; C07K14/00; C07K14/195; C07K14/305; C07K14/31; B01D2313/00; B01D2313/90; B01D2317/00; B01D2317/02
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
156 words
A method employing a homogeneous phase for the recovery of a peptide-containing compound, said method comprising the steps of (a) bringing said peptide-containing compound into contact with a solution containing a ligand attached to a carrier, said ligand and attached carrier being in soluble form and said ligand being capable by biospecific affinity of fixing onto the peptide-containing compound so as to form a homogeneous phase of a soluble complex of said carrier, said ligand and said peptide-containing compound in said solution; (b) separating contaminations having a molecular weight lower than the molecular weight of said soluble complex from said homogeneous phase containing said soluble complex without separating said soluble complex from said homogeneous phase; (c) liberating said peptide-containing compound from said soluble complex in said homogeneous phase to reform said ligand with attached carrier and said peptide-containing compound in said homeogeneous phase; and (d) separating and recovering said liberated peptide-containing compound from said homogeneous phase.
Claim 2
Independent Claim
156 words
A method employing a homogeneous phase for the recovery of a peptide-containing compound, said method comprising the steps of (a) bringing said peptide-containing compound into contact with a solution containing a ligand attached to a carrier, said ligand and attached carrier being in soluble form and said ligand being capable by biospecific affinity of fixing onto the peptide-containing compound so as to form a homogeneous phase of a soluble complex of said carrier, said ligand and said peptide-containing compound in said solution; (b) separating contaminations having a molecular weight lower than the molecular weight of said soluble complex from said homogeneous phase containing said soluble complex without separating said soluble complex from said homogeneous phase; (c) liberating said peptide-containing compound from said soluble complex in said homogeneous phase to reform said ligand with attached carrier and said peptide-containing compound in said homeogeneous phase; and (d) separating and recovering said liberated peptide-containing compound from said homogeneous phase.
Claim 3
Independent Claim
242 words
A method employing a homogeneous phase for the recovery of a peptide-containing compound from a solution containing said peptide-containing compound, said method comprising the steps of (a) subjecting said solution to a first membrane filtration so as to remove contaminants with molecular weights above a predetermined limit greater than the molecular weight of the peptide-containing compound to provide a first filtrate solution containing said peptide-containing compound; (b) bringing said first filtrate solution into contact with a ligand attached to a carrier, said ligand and attached carrier being in soluble form and said ligand being capable by biospecific affinity of fixing onto the peptide-containing compound so as to form a homogeneous phase of a soluble complex of said carrier, said ligand and said peptide-containing compound in said first filtrate solution; (c) subjecting the first filtrate solution containing said soluble complex to a second membrane filtration so as to remove contaminants from said first filtrate solution with molecular weights below a predetermined limit lower than the molecular weight of said soluble complex to provide a second filtered solution; (d) liberating said peptide-containing compound from the soluble complex in said second filtered solution to reform said ligand with attached carrier and said peptide-containing compound in said second filtered solution; and (e) subjecting said second filtered solution containing the liberated peptide-containing compound and the ligand with attached carrier to a third membrane filtration so as to filter the peptide-containing compound from the ligand with attached carrier.
Claim 4
Independent Claim
242 words
A method employing a homogeneous phase for the recovery of a peptide-containing compound from a solution containing said peptide-containing compound, said method comprising the steps of (a) subjecting said solution to a first membrane filtration so as to remove contaminants with molecular weights above a predetermined limit greater than the molecular weight of the peptide-containing compound to provide a first filtrate solution containing said peptide-containing compound; (b) bringing said first filtrate solution into contact with a ligand attached to a carrier, said ligand and attached carrier being in soluble form and said ligand being capable by biospecific affinity of fixing onto the peptide-containing compound so as to form a homogeneous phase of a soluble complex of said carrier, said ligand and said peptide-containing compound in said first filtrate solution; (c) subjecting the first filtrate solution containing said soluble complex to a second membrane filtration so as to remove contaminants from said first filtrate solution with molecular weights below a predetermined limit lower than the molecular weight of said soluble complex to provide a second filtered solution; (d) liberating said peptide-containing compound from the soluble complex in said second filtered solution to reform said ligand with attached carrier and said peptide-containing compound in said second filtered solution; and (e) subjecting said second filtered solution containing the liberated peptide-containing compound and the ligand with attached carrier to a third membrane filtration so as to filter the peptide-containing compound from the ligand with attached carrier.
Claim 5
Dependent Claim
14 words
A method according to claim 2, wherein said predetermined limit is 5×10 5 Dalton.
Claim 6
Dependent Claim
18 words
A method according to claim 2, wherein said peptide-containing compound is liberated through an alteration of the pH.
Claim 7
Dependent Claim
31 words
A method according to claim 4, wherein said alteration of pH is accomplished through addition of an acid so as to break the bond between the ligand and the peptide-containing compound.
Claim 8
Dependent Claim
27 words
A method according to claim 2, wherein said peptide-containing compound is liberated through the addition of a salt solution to increase the ionic strength of the solution.
Claim 9
Dependent Claim
31 words
A method according to claim 2, wherein said third membrane filtration is adapted so that it lets through the peptide-containing compound but retains the carrier with the ligand attached to it.
Claim 10
Dependent Claim
21 words
A method according to claim 7, wherein said third membrane filtration has a cut-off between 5×10 5 and 10 6 Dalton.
Claim 11
Dependent Claim
23 words
A method according to claim 7, wherein the carrier and the ligand attached to it from step (e) is re-used in step (b).
Claim 12
Dependent Claim
27 words
A method according to claim 9, wherein, prior to said re-use, the pH of the solution with the carrier and the ligand attached to it is restored.
Claim 13
Dependent Claim
36 words
A method according to claim 2, wherein a weak buffer solution is added in connection with said step (c) so as to maintain the pH of said solution containing the complex at about the neutral point.
Claim 14
Dependent Claim
31 words
A process according to claim 2, wherein said ligand is selected from the group consisting of immunoglobulins, Fc-receptors, surface receptors from bacteria with affinity for the Fc-part co-factors, and sugar-containing proteins.
Claim 15
Dependent Claim
15 words
A process according to claim 2, wherein said ligand is protein A from S. aureus.
Claim 16
Dependent Claim
20 words
A process according to claim 2, wherein said ligand is attached to said carrier by bonds of a covalent character.
Claim 17
Dependent Claim
28 words
A process according to claim 2, wherein said carrier is a soluble macromolecule of a molecular weight above the molecular weight of the peptide-containing compound to be recovered.
Claim 18
Dependent Claim
13 words
A process according to claim 15, wherein said macromolecule is a soluble sugar.
Claim 19
Dependent Claim
20 words
A process according to claim 16, wherein said soluble sugar is selected from the group consisting of cellulose and dextran.
Claim 20
Dependent Claim
12 words
A process according to claim 15, wherein said macromolecule is a polyacrylamide.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-10-02 | 1988-04-02 | 1988-10-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-10-02 | 1992-04-02 | 1992-10-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-10-02 | 1996-04-02 | 1996-10-02 | $7700.00 | Window Closed / Lapsed |